Evidence map›Paper›PMID 34834271›Full record

ArticlePharmaceutics2021

Blood-Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?

Guillaume Becker, Sylvia Da Silva, Amelia-Naomi Sabo, Maria Cristina Antal, Véronique Kemmel, Laurent Monassier

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Autophagy · 2024
    Article
  3. Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Guillaume BeckerLaboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire UR7296, Département Universitaire de Pharmacologie, Addictologie, Toxicologie et Thérapeutique, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Université de Strasbourg, 1 Rue Eugène Boeckel, CEDEX, 67085 Strasbourg, France.ORCID 0000-0003-2710-0960
Sylvia Da SilvaLaboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire UR7296, Département Universitaire de Pharmacologie, Addictologie, Toxicologie et Thérapeutique, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Université de Strasbourg, 1 Rue Eugène Boeckel, CEDEX, 67085 Strasbourg, France.
Amelia-Naomi SaboLaboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire UR7296, Département Universitaire de Pharmacologie, Addictologie, Toxicologie et Thérapeutique, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Université de Strasbourg, 1 Rue Eugène Boeckel, CEDEX, 67085 Strasbourg, France.
Maria Cristina AntalFaculté de Médecine, Institut d'Histologie-Service Central de Microscopie Électronique, Équipe IMIS-ICube UMR7357, Université de Strasbourg, 4 Rue Kirschleger, CEDEX, 67085 Strasbourg, France.
Véronique KemmelLaboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire UR7296, Département Universitaire de Pharmacologie, Addictologie, Toxicologie et Thérapeutique, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Université de Strasbourg, 1 Rue Eugène Boeckel, CEDEX, 67085 Strasbourg, France.ORCID 0000-0003-4680-4293
Laurent MonassierLaboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire UR7296, Département Universitaire de Pharmacologie, Addictologie, Toxicologie et Thérapeutique, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Université de Strasbourg, 1 Rue Eugène Boeckel, CEDEX, 67085 Strasbourg, France.
Hôpitaux Universitaires de Strasbourg · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serotonin affects many functions in the body, both in the central nervous system (CNS) and the periphery. However, its effect on the blood-brain barrier (BBB) in separating these two worlds has been scarcely investigated. The aim of this work was to characterize the serotonin receptor 5-HT

Indexed as

5-HT4 receptorblood–brain barrier permeabilityhCMEC/D3microvascular endothelial cellsprucaloprideserotonin

Identifiers

PMID34834271
PMCPMC8619119
OpenAlexW3208850244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.